Here's Why McKesson (MCK) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Reasons Why You Should Hold McKesson (MCK) Stock for Now
McKesson's (MCK) robust Biologics business raises optimism about the stock.
McKesson (MCK) Declines More Than Market: Some Information for Investors
In the latest trading session, McKesson (MCK) closed at $575.23, marking a -1.98% move from the previous day.
Here's Why McKesson (MCK) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investors Heavily Search McKesson Corporation (MCK): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
Why McKesson (MCK) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here is What to Know Beyond Why McKesson Corporation (MCK) is a Trending Stock
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
McKesson (MCK) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, McKesson (MCK) closed at $599.56, marking a -0.8% move from the previous day.
McKesson (MCK) Reaches 52-Week High: What's Aiding the Stock?
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
McKesson (MCK) Increases Despite Market Slip: Here's What You Need to Know
In the most recent trading session, McKesson (MCK) closed at $603.24, indicating a +0.05% shift from the previous trading day.
McKesson (MCK) Introduces FDA-Approved Prostate Cancer Drug
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients improved treatment options for prostate cancer.
McKesson (MCK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
McKesson (MCK) closed at $589.95 in the latest trading session, marking a -0.19% move from the prior day.
